TIRSF

TIRSF identifies and applies gene expression signatures to predict responses to immune checkpoint blockade (ICB) therapy in cancer patients.

Key Features:

• Signature Discovery Module: Constructs gene signatures tailored to predict responses to immune checkpoint blockade (ICB) therapy and evaluates their performance.
• Response Prediction Based on TIRSF Signatures: Applies constructed signatures to immunotherapy samples to predict response and perform prognostic analyses.
• Integration of Existing Signatures: Incorporates 24 published gene signatures for ICB therapy response prediction for application to new datasets.

Scientific Applications:

• Patient stratification: Identifies patient subsets more likely to respond to ICB therapy based on gene expression signatures.
• Predictive biomarker development: Facilitates development and evaluation of gene-expression-based biomarkers for ICB response.
• Prognostic analysis: Enables prognostic assessments of clinical outcomes using applied signatures.

Methodology:

Signature construction, performance evaluation, application of signatures to immunotherapy samples for response prediction and prognostic analysis, and integration of 24 published ICB gene signatures.